The immunogenicity of oral poliomyelitis vaccine in a primary vaccination series at 2, 4 and 6 months given concurrently with Hib, hepatitis B and diphtheria, tetanus and whole-cell pertussis vaccines administered as three separate injections or as a combination pentavalent vaccine

Vaccine

Volumn 21, Issue 21-22, 2003, Pages 2906-2910

  Hogg, Katharine ^a,b   Hogg, Geoff ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

Immunogenicity; Oral poliomyelitis vaccine; Vaccine

Indexed keywords

DIPHTHERIA VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; NEUTRALIZING ANTIBODY; ORAL POLIOMYELITIS VACCINE; PERTUSSIS VACCINE; TETANUS TOXOID; VACCINE;

ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INFANT; MAJOR CLINICAL STUDY; NORMAL HUMAN; POLIOMYELITIS; PRIORITY JOURNAL; PROTECTION; VACCINATION; VACCINE PRODUCTION;

EID: 0038513393     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(03)00133-6     Document Type: Article

References (31)

1. World Health Organisation Western Pacific Regional Office. Kyoto declaration: polio-free 2000. Japan: Influx Com. Inc; 2000.
2. National Health and Medical Research Council. The Australian immunisation procedures handbook. Canberra: Australian Government Publishing Service; 1994. p. 47.
3. Hogg K., Hogg G., Lester R., Uren E. Immunity to poliomyelitis in Victorians. Aust. N. Z. J. Public Health. 26(5):2002;432-436.
4. Commonwealth Department of Health and Aged Care. Australian standard vaccination schedule - from 1 May 2000. Available from: http://www.health.gov.au/hfs/pubhlth/immunise/schedule_n2.htm [cited 5 January 2000].
5. Nolan T., Hogg G., Darcy M., Skeljo M., Carlin J., Boslego J. A combined liquid Hib (PRP-OMPC), hepatitis B, diphtheria, tetanus and whole-cell pertussis vaccine: controlled studies of immunogenicity and reactogenicity. Vaccine. 17:2001;2127-2137.
6. Badewitz L, Tuckwell K, editors. 1993 MIMS annual. 17th ed. Australia: Australian Print Group; 1993.
7. Guidelines for WHO/EPI collaborative studies on poliomyelitis: standard procedure for determining immunity to poliovirus using the microneutralization test. WHO/EPI/GEN/93.9.
8. Wood D., Heath A. The second international standard for anti-poliovirus sera types 1, 2, and 3. Biologicals. 20:1992;203-211.
9. National Institute for Biological Standards and Control. Second international standard anti-measles serum, human and second international standard anti-poliovirus serum, types 1, 2 and 3; 66/202.
10. Sabin A.B. Inadequate serological surveys for immunity to poliomyelitis. Med. J. Aust. 1:1983;100-102.
11. Nishio O., Ishihara Y., Sakae K., Nonmura Y., Kuno A., Yasukawa S.et al. The trend of acquired immunity with live poliovirus vaccine and the effect of vaccination: follow-up of vaccininees for 10 years. J. Biol. Stand. 12:1984;1-10.
12. Cabasso V.J., Nozell H., Ruegsegger J.M., Cox H.R. Poliovirus antibody 3 years after oral trivalent vaccine. J. Pediatr. 68:1966;199-203.
13. Triassi M., Ribera G., Barruffo L., Barbone S., Medda E., Grandolfo M.E. Persistence of immunity to poliomyelitis among a southern population that received four doses of OPV 5 to 15 years before. Eur. J. Epidemiol. 12:1996;5-8.
14. Sabin A.B. Present position of immunization against poliomyelitis with live virus vaccine. Br. Med. J. 1:1959;663-682.
15. Bellelli E., Tanzi M.L., Bocelli V., Bracchi U., Affanni P. Antipoliomyelitis immunity status among a population that was regularly vaccinated 11-12 years before. Eur. J. Epidemiol. 7:1991;605-611.
16. Halsey N., Galazka A. The efficacy of DPT and oral poliomyelitis immunization schedules initiated from birth to 12 weeks of age. Bull. WHO. 63(6):1985;1151-1169.
17. McBean AM, Thoms ML, Albrecht P, Cuthie J, Bernier R, and The Field Staff and Co-ordinating Committee. Serological response to oral polio vaccine and enhanced-potency inactivated polio vaccines. Am J Epidemiol 1988;128(3):615-28.
18. Plotkin S., Koprowski H., Stokes J. Clinical trials in infants of orally administered attenuated poliomyelitis viruses. Pediatrics. 23:1959;1041-1062.
19. Altman DG, Machin D, Bryant TN, Gardner MJ, editors. Statistics with confidence. 2nd ed. Bristol, UK: BMJ Books; 2000.
20. Bryant T. Confidence interval analysis, Version 2.0.0, Build 41. University of Southampton, USA, 2000.
21. Dean AG, et al. Epi Info, Version 6: a wordprocessing, database and statistical program for epidemiology on microcomputers. Atlanta (GA): Centres for Disease Control and Prevention; 1995.
22. Faden H., Modlin J., Thoms M.L., McBean A.M., Ferdon M.B., Ogra P.L. Comparative evaluation of immunization with live attenuated and enhanced potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune response. J. Infect. Dis. 162:1990;1291-1297.
23. Murphy W. Response of infants to trivalent poliovirus vaccine (Sabin strains). Pediatric. 40(6):1967;980-985.
24. Hardy G.E., Hopkins C.C., Linnemann C.C., Hatch M.H., Chambers J.C., Witte J. Trivalent oral poliovirus vaccine: a comparison of two infant immunization schedules. Pediatric. 45(3):1970;444-448.
25. Baston R., Christie A., Cheatham W.J. The infant's serological response to live poliomyelitis virus vaccine. J. Am. Med. Assoc. 180(3):1962;193-197.
26. Lahrech M.T., Caudrelier P. Immunological response of Moroccan children and newborns to oral poliovirus vaccine prepared on vero cells. Vaccine. 8:1990;306-307.
27. Simasathien S., Migasena S., Beuvery C., van Steenis G., Samakoses R., Pitisuttitham P.et al. Comparison of enhanced potency inactivated poliovirus vaccine (EIPV) versus standard oral poliovirus vaccine (OPV) in Thai infants. Scand. J. Infect. Dis. 26:1994;731-738.
28. Lennette E., Schmidt N. Studies of the development and persistence of complement-fixing and neutralizing antibodies in human poliomyelitis. Am. J. Hyg. 65:1957;210-232.
29. Sabin A. Properties and behaviour of orally administered attenuated poliovirus vaccine. J. Am. Med. Assoc. 164:1957;1216-1223.
30. Sabin A. Prevention of poliomyelitis by vaccination. Adv. Pediatr. 10:1958;197-240.
31. Paul J., Riordan J., Melnick J. Antibodies to three different antigenic types of poliomyelitis virus in sera from north Alaskan Eskimos. Am. J. Hyg. 54:1951;275-285.